Procyrion, Inc. Chosen to Present at EuroPCR 2017 in Paris


Houston, TX (May 9, 2017) – Heart pump developer Procyrion, Inc. has been selected to participate in the 2017 EuroPCR, which will take place May 16th to 19th at the Palais des Congrès in Paris, France. Chief Scientific Officer Jace Heuring will deliver a presentation and discuss Aortix™, a percutaneous chronic intra-aortic pump for hemodynamic support.

Procyrion’s award winning technology, which is thinner than a #2 pencil, is the first catheter-based heart pump designed specifically for the ambulatory treatment of NYHA Class III-IVa heart failure patients who are too sick for medication alone, but not sick enough for risky surgical interventions (e.g. an LVAD or transplant). The small but powerful micro-pump is placed downstream of the heart in a simple cath-lab procedure and works to support heart function by accelerating native blood flow. Heart failure is the next frontier in cardiovascular interventions, and Aortix is potentially a significant advancement in treatment.  

EuroPCR is the official annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and the World-Leading Course in Interventional Cardiovascular Medicine. It functions as the global forum for sharing and consensus building among interventional communities through interactive workshops, lectures given by leading experts in the field, presentations of new products and R&D developments, and discussions on new technologies, trials, and the latest controversies.

“Heart failure affects millions and for many of those patients there are no good options. We believe the novel approach embodied by Aortix could offer improved quality of life and lower treatment costs,” stated Heuring. “Presenting at EuroPCR gives us the opportunity to discuss exactly how Aortix can do that.”

Dr. Heuring’s presentation will take place Tuesday, May 16th, during the Device-based management in advanced chronic heart failure: are we there yet? session at 4:15 PM local time.



Houston-based medical device firm Procyrion, Inc. is developing the first catheter-deployed, intra-aortic pump for ambulatory use.  The device is designed to rest and heal the heart by reducing afterload while simultaneously improving blood flow to vital organs. This groundbreaking cardiology tool, conceived by cardiologist Dr. Reynolds M. Delgado, III, medical director of Mechanical Support Devices in Heart Failure at the Texas Heart Institute, is expected to provide a minimally invasive treatment option for millions of chronic heart failure patients.  For more information, visit or call 713.579.9227.

Read More